Latest News About Bayer

Here are the latest Bayer updates gathered from public sources:

• Bayer is in focus for its litigation-related challenges around Roundup and glyphosate, with ongoing discussions about regulatory and legal changes that could affect production and product availability in the U.S. market.[1]

• In business news, Bayer has been active in strategic moves, including divestitures and acquisitions in recent months, such as the sale of certain Crop Science assets and the potential acquisition of Perfuse Therapeutics to bolster its ophthalmology pipeline.[3][1]

• Market coverage shows Bayer receiving continued attention from analysts, with several firms maintaining favorable ratings and highlighting strategic partnerships and pipeline updates, including recent data on Asundexian and other FXIa inhibitors.[2]

• Bayer’s U.S. newsroom and global Bayer Newsroom remain key sources for official updates, including product approvals, clinical trial results, and company strategy announcements.[5][6]

• Recent earnings context suggests Bayer benefitted from quarterly results while managing macro and litigation-related uncertainties, with commentary on outlook and earnings trajectory.[3]

If you’d like, I can drill into a specific area (Roundup litigation status, crop science divestitures, or pipeline updates for a particular drug) and pull the most precise, dated items with brief excerpts. Also, tell me if you want a short timeline of developments over the past six months or a chart of stock reaction around key Bayer announcements.